Evonik's €24 Bid Is Only as Strong as the Three Yeses Behind It
Published on 10/24/2026 at 12:21 | Editorial boerse-global.de
BASF's reported €24-per-share approach to Evonik has handed shareholders a clear price tag — and a reminder that a headline number is not a deal. The offer, first reported by Reuters and picked up by Handelsblatt, values the specialty chemicals group at roughly €11.2 billion, up from an earlier €22.15 per share. Neither company would comment, and no formal public takeover offer has been confirmed.
The market wasted no time pricing the news: Evonik shares rose 3.4% on the reports. Yet the stock closed Friday at €21.40, below the reported bid — a gap that reflects hope rather than a locked-in return. Turning that spread into a realisable gain requires an actual offer document with binding terms, not just a bigger number circulating in the press.
Three Gatekeepers Stand Between Bid and Deal
Price is the easy part to report. The harder questions sit with the RAG-Stiftung, the workforce on both sides of the transaction, and competition regulators.
The RAG-Stiftung is Evonik's dominant shareholder, holding 44% of the shares according to a Handelsblatt report dated 9 October. Its board declined at the time to take a position on the BASF approach, deferring to the executive boards of both companies. Europa Press has since described the foundation's backing as decisive to the outcome. No public endorsement of the sweetened offer has emerged, and Reuters reported that neither Evonik nor the foundation would comment.
Should investors sell immediately? Or is it worth buying Evonik?
That silence cuts both ways. It is not a rejection, but it is a long way from the approval a transaction of this scale would need.
Promises to Evonik, Demands from Ludwigshafen
BASF has moved early to smooth the labour side — at least for Evonik's employees. In a video message on Thursday, chief executive Markus Kamieth pledged to honour Evonik's existing site agreements, rule out compulsory redundancies until 2032, and leave collective bargaining and social partnership untouched.
BASF was careful to frame that as a statement of intent, not an offer: formal conditions would only appear in an offer document. The distinction matters for investors weighing how much of the reported bid is already contractually nailed down.
Complicating the picture, BASF's own works council chief, Sinischa Horvat, is pressing for job security and investment commitments at Ludwigshafen, warning that financing the acquisition must not hollow out the site's existing agreement. Any concession extended to Evonik therefore has to sit alongside the interests of the buyer's own workforce.
A Cartel Review, Not Just a Price Tag
The industrial case has been aired too. ZDF reported on complementary portfolios and potential advantages in raw material supply and value creation. An expert cited by the broadcaster noted that in individual specialty chemicals markets, BASF and Evonik together would frequently command more than 50% of global market share — making antitrust scrutiny pivotal.
Political resistance is already on record. North Rhine-Westphalia's economy minister, Mona Neubaur, spoke out against a BASF takeover of Evonik in the state parliament on 14 October, according to Handelsblatt. That is not proof of legal failure, but it signals that a higher price alone will not settle the argument.
Evonik at a turning point? This analysis reveals what investors need to know now.
What Investors Should Watch Next
Two tracks now run in parallel. On the first, the key variable is whether BASF converts its reported approach into a formal public offer, letting shareholders assess concrete conditions rather than a press figure. Evonik is reviewing the bid, Reuters reported, but review, launch and completion are separate stages and deserve separate weight.
On the second, Evonik's standalone story still counts. The company is scheduled to publish its third-quarter 2026 interim statement on 3 November 2026 — a date that could reframe the valuation if takeover expectations fade. Anyone holding the stock chiefly for the bid would then need to lean on operating performance, with the reported price offering no reliable guide to an achievable exit.
For now, the €24 figure is a benchmark, not a guarantee. The decisive question is whether the owner, the workforces and the competition authorities can be brought into the same framework — and on that, the silence is still louder than the price.
Ad
Evonik Stock: New Analysis - 24 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
